Sagar Bhagwat, MBA, MS

CRS:

BJMC

Role:

Administrative and Finance

Position:

Senior Grants and Contracts Analyst

Mr. Bhagwat is the Senior Grants and Contracts Analyst for Johns Hopkins Center for Clinical Global Health Education (CCGHE) and manages the financial activities of the center along with the Fiscal Operations Manager. He works on all aspects of sponsored research pre and post award, including development and management of federal, state, private, and foundation grants/contracts. He is the primary contact for all outgoing CCGHE subcontracts and works closely with international collaborators in India, Uganda, United Kingdom as well as domestic collaborators within the US.
 
Mr. Bhagwat is a part of the CCGHE leadership group that provides financial/administrative support and oversight to the Johns Hopkins entities in India (Johns Hopkins India Pvt. Ltd & Johns Hopkins India Foundation). He works closely with external funding agencies such as US National Institutes of Health (NIH), CRDF Global, Maryland Department of Health (MDH) among others and internally with the Office of Research Administration (ORA), the Office of Sponsored Projects and Shared Services (SPSS), the Department Finance Office at the Johns Hopkins University School of Medicine.
 
He joined Johns Hopkins in 2016 with several years of accounting and finance experience. He received a dual Master’s degree in Business Administration (MBA in Operations Management) and Science (MS in Chemical & Biomedical Engineering) from the Cleveland State University.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

P1108: A Phase I/II, Open-Label, Single Arm Study to...

This purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquiline (BDQ) in...

Read More

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More